By Fineline Cube 
Chinese partners Biocytogen Pharmaceuticals (Beijing) Co., Ltd. (HKG: 2315) and Chia Tai Tianqing announced that they have received clinical approval from the National Medical Products Administration (NMPA) for their co-developed NTB003 (BCG009), a second-generation anti-IGF-1R antibody. The drug is intended for the treatment of thyroid eye disease (TED).
NTB003 Development and Advantages
NTB003 was discovered and optimized using Biocytogen’s proprietary RenMab platform. Chia Tai Tianqing led the CMC process development, GLP safety evaluation, and IND registration. Compared to first-generation approved drugs, NTB003 shows improvements in molecular affinity, druggability, and half-life. It has demonstrated potent signal-blocking effects in vitro and can effectively inhibit hyaluronic acid (HA) release.
Collaboration and Next Steps
Chia Tai Tianqing will accelerate clinical trials and commercialization in China. Biocytogen will lead overseas licensing and partnership efforts for NTB003.-Fineline Info & Tech